21) Chemical Therapeutics
Abstract
Focuses on pretreatment and post treatment strategies to effectively minimize injuries resulting from exposure to CWAs. This effort involves the development of neuroprotectants, anticonvulsants, and improved therapies for brain enzyme reactivation. Supports eventual FDA licensure of new compounds or to identify licensed products for use in the treatment of chemical warfare casualties. This effort is being separated into four thrust areas starting in FY21: Nerve Agent Prophylaxis/Pretreatments, Pharmaceutical Based Agents (PBAs), and Reactivators of AChE as Therapeutics (ReACT).
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2022
- Source ID
- 8c19596009c285fb40e3936e1d1b5e7f